Galderma raises 2026 net sales growth forecast to 22.5%-23.5% at constant currency

• Galderma raised its 2026 net sales growth forecast to 22.5%-23.5% at constant currency from 19%-21%.
• Core EBITDA margin guidance remained approximately 26% at constant currency, despite growth investments.
• Nine-month net sales reached USD 4.77 billion, up 25.1% at constant currency, with volume the primary growth driver.
• The ZO Skin Health acquisition is expected to be neutral for core EPS in 2027, but slightly dilutive to core EBITDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galderma Group AG published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.